The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy,...) in patients with pancreatic adenocarcinoma. The effectiveness and tolerance of these treatments in current practice is also evaluated.
Patient with histologically confirmed pancreatic adenocarcinoma.
Disease at a resectable, borderline, locally advanced, initially metastatic, or recurrent stage after surgery
Diagnosis between January 1, 2003, and December 31, 2030.
First-line treatment with chemotherapy and/or radiotherapy and/or clinical trials.
Patient under guardianship, curatorship, or judicial protection.
Pregnant or breastfeeding women.
Any medical, psychological, or social situation that could prevent compliance with the protocol as assessed by the investigator.
Refusal to participate in the study
Retro-prospective (diagnosis between 2003 and 2022) and prospective (diagnosis between 2023 and 2030) cohorts of patients with pancreatic adenocarcinoma
Cohort
Other
Not listed
Overall Survival (OS) rate
Defined as the time interval between the start date of treatment (surgery, first cycle of L1 chemotherapy, or first radiotherapy session) and the date of death regardless of the cause. Living or lost to follow-up patients will be censored at the date of the last news
Progression-free survival (PFS) rate
Defined as the time interval between the start date of treatment (surgery, first cycle of L1 chemotherapy, or first radiotherapy session) and the date of first progression or date of death regardless of the cause. Living patients without progression or lost to follow-up will be censored at the date of the last news
Number of patient with objective response rate
Evaluation according to RECIST v1.1, Choi or iRECIST criteria. Study the population followed for pancreatic adenocarcinoma according to tumor stages (localized, borderline, locally advanced, metastatic or recurrent after surgery) and according to treatments.
Number of patient with stability rate
Evaluation according to RECIST v1.1, Choi or iRECIST criteria. Study the population followed for pancreatic adenocarcinoma according to tumor stages (localized, borderline, locally advanced, metastatic or recurrent after surgery) and according to treatments.
Number of patient with tumor progression
Evaluation according to RECIST v1.1, Choi or iRECIST criteria. Study the population followed for pancreatic adenocarcinoma according to tumor stages (localized, borderline, locally advanced, metastatic or recurrent after surgery) and according to treatments.
Click on the lead sponsor to view all of their trials.
